Philip B. Gorelick, MD, discusses FAST-MAG trial results

  • March 12, 2014

SAN DIEGO — In this video, Philip B. Gorelick, MD, professor of translational science and molecular medicine at Michigan State University College of Human Medicine, discusses the results from the FAST-MAG trial, presented at the International Stroke Conference.

Researchers evaluated 1,700 patients within 2 hours of stroke onset, who received either 4 mg magnesium in the field and 16 g magnesium infusion over the subsequent 24 hours, or placebo. The aim of the phase 3 trial was to assess the impact of early administration of intravenous magnesium on outcomes from acute ischemic stroke, according to the modified Rankin scale.

More »

Additional headlines from International Stroke Conference

See All »